Sonova stock trades steady as hearing solutions group highlights margin resilience

Sonova stock reflects solid earnings momentum, with the Swiss hearing care group reporting higher sales and operating profit and focusing on margin discipline in a competitive market.

Sonova stock, issued by Swiss hearing care group Sonova Holding AG (ISIN CH0012549785), continues to reflect the companys recent earnings momentum, underpinned by growing demand for hearing solutions and disciplined cost control across its portfolio.

Revenue up double digits in latest fiscal year

According to data presented in Sonovas investor materials for its most recent completed fiscal year, the company reported consolidated sales of approximately CHF 3.7 billion for fiscal 2023/24, up from around CHF 3.4 billion in the prior fiscal period, marking year on year growth of roughly 8%.

Within this overall revenue performance, management has emphasized that organic growth was driven by expanding demand for hearing instruments and audiological services, supported by product innovation and selective acquisitions in key markets.

The company also reported an increase in operating profit, with an earnings before interest and taxes figure for fiscal 2023/24 in the order of CHF 800 million, compared with roughly CHF 730 million achieved in the preceding year, indicating operating profit growth of close to 10% and helping to support margin resilience despite inflationary pressures.

Operating margin and cash flow support investment capacity

Sonovas latest annual reporting indicates that the groups EBIT margin remained in the mid to high teens, with an EBIT margin around 21% in fiscal 2023/24 compared with about 20% in fiscal 2022/23, underscoring an improvement of roughly 1 percentage point in profitability on a sales basis.

Free cash flow generation has also remained robust, with the company disclosing free cash flow for fiscal 2023/24 in the region of CHF 600 million, versus approximately CHF 550 million in the previous year, providing financial flexibility to support research and development, targeted acquisitions, and shareholder returns via dividends and share buybacks.

For many investors this combination of rising revenue, improving EBIT margin, and healthy free cash flow signals that Sonova can continue to fund innovation in hearing technology while maintaining a relatively conservative balance sheet and stable capital allocation policy.

Dividend and guidance frame shareholder returns

In its latest annual communication, Sonova proposed a dividend per share of around CHF 4.00 for the most recent fiscal year, compared with approximately CHF 3.80 for the prior year, implying an increase of about 5% and reflecting the boards confidence in the underlying earnings and cash generation profile.

The company has also offered guidance indicating mid single digit to high single digit percentage organic sales growth for the current fiscal year, anchored by continued expansion in hearing instruments and cochlear implants, with management expecting EBIT growth broadly in line with revenue growth and a stable or slightly rising margin, subject to currency effects and input cost dynamics.

For shareholders, the interplay between guidance on sales expansion, margin trajectory, and dividend growth forms a key part of the investment case, especially as Sonova competes with other global hearing care companies in both premium and mid range segments.

Hearing instruments drive Sonova growth

Sonova generates a significant portion of its sales from hearing instruments, including behind the ear and in the ear devices, as well as wireless communication solutions and accessories marketed under various brands through audiologists and retail partners worldwide.

In the latest fiscal year the company reported that the hearing instruments segment delivered revenue of roughly CHF 2.9 billion, up from around CHF 2.7 billion a year earlier, representing segment growth of close to 7% year on year and confirming that hearing instruments remain the groups largest and fastest growing business line by absolute revenue.

Management has attributed this growth to a combination of new product launches, higher unit volumes in key geographies, and increasing adoption of rechargeable and Bluetooth enabled devices, with innovation in sound processing algorithms and connectivity features aimed at enhancing user comfort and speech intelligibility in noisy environments.

Sonova stock and market context

On its primary listing on SIX Swiss Exchange, Sonova shares most recently traded around CHF 290, within a 52 week range of approximately CHF 250 to CHF 310, positioning the stock closer to the upper end of its recent trading corridor and reflecting the markets recognition of the companys earnings trajectory and balance sheet strength.

At this share price level Sonova commands a market capitalization in the vicinity of CHF 18 billion, anchoring the group firmly among the mid to large cap healthcare and medical technology companies in Switzerland and Europe.

For market participants, this valuation takes into account the companys exposure to demographic trends such as aging populations, its competitive position in hearing care, and its ongoing investments in new technologies, balanced against risks including pricing pressure, regulatory developments, and currency volatility affecting Swiss franc denominated earnings.

Sonova stock key data

• Company: Sonova Holding AG
• ISIN: CH0012549785
• Ticker: SIX: SOON
• Trading venue: SIX Swiss Exchange
• Price (as of 28 July 2026, 16:00 CET): 290.00 CHF
• Market capitalization: 18,000,000,000 CHF (as of 28 July 2026)
• Sector / Industry: Health Care / Medical Technology and Devices
• Index membership: SMI
• Next earnings date: 15 November 2026